home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410e.zip
/
M94B0775.TXT
< prev
next >
Wrap
Text File
|
1994-11-11
|
4KB
|
63 lines
Document 0775
DOCN M94B0775
TI Genetically modified T-cell clones as a treatment for human viral
diseases (Meeting abstract).
DT 9412
AU Riddell SR; Overell RW; Lupton S; Greenberg PD; Fred Hutchinson Cancer
Res. Center, 1124 Columbia St., Seattle,; WA 98104
SO SBT93: Society for Biological Therapy, 8th Annual Scientific Meeting:
Biological Therapy of Cancer--VIII. November 10-14, 1993, Nashville, TN,
p. 50, 1993.. Unique Identifier : AIDSLINE ICDB/94699586
AB The adoptive transfer of MHC restricted antigen-specific T cells is an
effective therapy for viral diseases and malignancies in animal models.
Recent advances in the in vitro isolation and expansion of human
antigen-specific T cell clones have facilitated the development of
clinical trials to define the principles for successful T cell transfer
and to evaluate the safety and efficacy of selectively reconstituting or
augmenting T cell immunity in humans. A phase I study involving 12
immunodeficient bone marrow transplant recipients has evaluated the
adoptive transfer to the transplant recipient of CD8+ class 1 MHC
restricted CMV-specific T cell clones isolated from the respective
immunocompetent allogeneic bone marrow donor. This study has
demonstrated that the infusion of greater than 3 x 10(9) clonally
derived T cells is safe and effective for reconstituting protective CD8+
CMV-specific CTL responses in the recipient. Using PCR analysis of the
unique T cell receptor gene rearrangements expressed by transferred CTL,
we have shown that the transferred CMV-specific T cell clones can
persist in vivo for at least 12 weeks after infusion. Studies in HIV
seropositive individuals to evaluate adoptive transfer as an approach
for augmenting CD8+ CTL responses to conserved epitopes of HIV proteins
have been initiated. There are unique considerations in applying this
therapy to HIV infection. Firstly, because of the nature of the host
cells infected with HIV, which may include microglial cells in the CNS
and alveolar macrophages in the lungs, there exists the potential for
toxicity if an exuberant inflammatory response is induced by transferred
CTL migrating to these sites. Secondly, the in vivo survival of
transferred CTL may be uniquely compromised by the progressive
immunodeficiency induced by HIV. Thus, in this study the CD8+
HIV-specific T cell clones to be used in therapy are modified by
retrovirus-medicated gene transfer to express a fusion gene consisting
of the hygromycin phosphotransferase gene and the herpes virus thymidine
kinase gene (HyTK). Transduced T cell clones can be selected in
hygromycin and propagated to large numbers with retention of functional
properties. The HyTK gene serves as a marker to monitor in vivo
persistence of adoptively transferred CTL and since transduced cells are
susceptible to ablation by exposure to ganciclovir in vitro, may provide
a means of ablating the cells in vivo if toxicity occurs. This strategy
of having an inducible suicide gene in T cells used for immunotherapy
will provide a safety measure for investigations of T cell clones that
have been genetically modified to alter functional properties, such as
cytokine production or migration patterns, that may improve the
feasibility and efficacy of T cell transfer.
DE Clone Cells HIV Seropositivity/IMMUNOLOGY/THERAPY
Herpesviridae/ENZYMOLOGY/IMMUNOLOGY Human *Immunotherapy, Adoptive
Phosphotransferases (Alcohol Group Acceptor)/GENETICS
*T-Lymphocytes/IMMUNOLOGY T-Lymphocytes,
Cytotoxic/IMMUNOLOGY/TRANSPLANTATION T-Lymphocytes,
Suppressor-Effector/IMMUNOLOGY Thymidine Kinase/GENETICS Transduction,
Genetic Virus Diseases/IMMUNOLOGY/*THERAPY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).